Abstract
Sarcomas are malignant mesenchymal tumors of variable aggressiveness characterized by a substantial invasive and metastatic potential. In this review we discuss current results of pharmacological targeting of Rho/ROCK signaling in tumor cells, and the growing evidence supporting the hypothesis that Rho/ROCK dependent amoeboid mode of invasion could play a substantial role in metastatic potential of cells of malignant tumors, particularly of sarcomas. We attempt to cover pharmacological, biological and pathological aspects of the problematic in a multidisciplinary manner, from the views of molecular biology to medical practice. We are presenting evidence that blockade of Rho/ROCK pathway decreases amoeboid tumor cell invasion in vitro and substantially attenuates tumor growth and metastasis in vivo. While ROCK inhibitors have been used for a long time in treatment of cardiovascular diseases, the potential use of ROCK inhibitors to treat cancer metastasis has been considered only very recently. We propose that determination of the invasion mode that prevails in a particular sarcoma tumor, together with appropriate use of Rho/ROCK inhibitors could significantly improve the effectiveness of sarcoma tumor treatment in the future.
Keywords: Sarcoma, Rho, ROCK, invasiveness
Current Cancer Drug Targets
Title: ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Volume: 10 Issue: 2
Author(s): S. Micuda, D. Rosel, A. Ryska and J. Brabek
Affiliation:
Keywords: Sarcoma, Rho, ROCK, invasiveness
Abstract: Sarcomas are malignant mesenchymal tumors of variable aggressiveness characterized by a substantial invasive and metastatic potential. In this review we discuss current results of pharmacological targeting of Rho/ROCK signaling in tumor cells, and the growing evidence supporting the hypothesis that Rho/ROCK dependent amoeboid mode of invasion could play a substantial role in metastatic potential of cells of malignant tumors, particularly of sarcomas. We attempt to cover pharmacological, biological and pathological aspects of the problematic in a multidisciplinary manner, from the views of molecular biology to medical practice. We are presenting evidence that blockade of Rho/ROCK pathway decreases amoeboid tumor cell invasion in vitro and substantially attenuates tumor growth and metastasis in vivo. While ROCK inhibitors have been used for a long time in treatment of cardiovascular diseases, the potential use of ROCK inhibitors to treat cancer metastasis has been considered only very recently. We propose that determination of the invasion mode that prevails in a particular sarcoma tumor, together with appropriate use of Rho/ROCK inhibitors could significantly improve the effectiveness of sarcoma tumor treatment in the future.
Export Options
About this article
Cite this article as:
Micuda S., Rosel D., Ryska A. and Brabek J., ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas, Current Cancer Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/156800910791054202
DOI https://dx.doi.org/10.2174/156800910791054202 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The IFN-λ Family (IL-28/29)
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Four Major Factors Regulate Phosphatidylinositol 3-kinase Signaling Pathway in Cancers Induced by Infection of Human Papillomaviruses
Current Medicinal Chemistry Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry MicroRNA and Bone Tumor: To Up Date
Current Signal Transduction Therapy Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Small Molecule Inhibitors of NF-κB and JAK/STAT Signal Transduction Pathways as Promising Anti-Inflammatory Therapeutics
Mini-Reviews in Medicinal Chemistry Biosafety of Onco-Retroviral Vectors
Current Gene Therapy Update on Hsp90 Inhibitors in Clinical Trial
Current Topics in Medicinal Chemistry Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Cell Adhesion Molecules and Cadmium
Current Chemical Biology Lanthionine Synthetase Component C-Like Protein 2: A New Drug Target for Inflammatory Diseases and Diabetes
Current Drug Targets Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Plasminogen Activator Inhibitor-1 in Tumor Growth, Angiogenesis and Vascular Remodeling
Current Pharmaceutical Design Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Non-Camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Targeting Gene Therapy for Prostate Cancer
Current Pharmaceutical Design Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design